Daniel Catenacci, MD, University of Chicago Medicine

Articles

Emerging Agents and Biomarkers in Gastric and GEJ Cancers 

August 2nd 2021

Daniel Catenacci, MD, and Sam Klempner, MD, conclude their discussion by examining emerging agents and biomarkers for the management of advanced gastric and esophagogastric junction cancers.

Sequencing After Progression on IO-Based Therapy for mGC

August 2nd 2021

Experts in the management of gastric cancer discuss best practices for monitoring signs and symptoms of disease progression and explore factors to consider when switching therapies in later lines of treatment.

Frontline Therapy for Metastatic PD-L1–, HER2+ Gastric Cancer

August 2nd 2021

Gastric cancer specialists emphasize the importance of communication and education when selecting first-line treatment for patients with PD-L1-negative, HER2-positive disease.

Biomarker Testing for Gastric and GEJ Cancers 

July 26th 2021

Experts in gastrointestinal oncology review the challenges associated with molecular testing and the role of biomarker testing on disease management. 

KEYNOTE-811: IO-Based Therapy for HER2+ Gastric Cancer

July 26th 2021

Sam Klempner, MD, and Daniel Catenacci, MD, discuss the KEYNOTE-811 study of pembrolizumab plus trastuzumab in combination with chemotherapy in patients with HER2-positive disease.

CHECKMATE649: Safety Profile and Toxicity Management

July 19th 2021

Thought leaders in gastric and GEJ cancers review safety outcomes from the CHECKMATE649 trial presented at the 2021 ASCO annual meeting.

CHECKMATE649: Trial Design and Efficacy Data

July 19th 2021

Key opinion leader in gastric cancer, Daniel Catenacci, MD, leads a discussion on the study design, patient population, and results from the CHECKMATE649 trial of nivolumab and chemotherapy in patients with gastric or GEJ cancers.

Recent FDA Approvals in Gastric and GEJ Cancers

July 12th 2021

Daniel Catenacci, MD, and Sam Klempner, MD, consider the overall impact of recently approved immunotherapy-based regimens for gastric and gastroesophageal junction cancers.

Historical Perspective on Treatment of Gastric and GEJ Cancers 

July 12th 2021

Experts in the management of gastric cancer provide a historical perspective on available treatment options.

Pancreatic Cancer Updates

August 10th 2020

Liver Cancer Updates

August 10th 2020

Gastric Cancer Updates

August 10th 2020

Colorectal Cancer Updates

August 10th 2020

Dr. Catenacci on the Challenges of Developing Novel Therapies in Gastroesophageal Cancer

July 2nd 2020

Daniel Catenacci, MD, discusses the challenges of developing novel therapies in gastroesophageal adenocarcinoma.

Dr. Catenacci on Treatment Selection in Esophagogastric Junction Adenocarcinoma

December 7th 2019

Daniel Catenacci, MD, discusses factors that may guide treatment selection for patients with esophagogastric junction adenocarcinoma.

Dr. Catenacci on Study of Margetuximab Plus Pembrolizumab in Gastric/GEJ Cancer

March 1st 2018

Daniel Catenacci, MD, medical oncologist, assistant professor of medicine, University of Chicago Medicine, discusses a study of margetuximab (MGAH22-10) plus pembrolizumab (Keytruda) in gastroesophageal junction (GEJ) or gastric adenocarcinoma.

Dr. Catenacci on Results of Margetuximab Plus Pembrolizumab in Gastric/GEJ Cancer

January 20th 2018

Daniel Catenacci, MD, medical oncologist, assistant professor of medicine, Univeristy of Chicago Medicine, discusses margetuximab (MGAH22-10) plus pembrolizumab (Keytruda) as treatment for patients with advanced HER2-positive gastroesophageal junction (GEJ) or gastric adenocarcinoma during the 2018 Gastrointestinal Cancers Symposium.